| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Fluorophenylboronic acid does not have a defined biological target as it is a synthetic reagent rather than a pharmacologically active compound. However, it has been used in the discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase (FAAH). Boronic acids can act as reversible covalent inhibitors of serine hydrolases and other enzymes with active-site nucleophiles. The fluorine substituent may enhance binding affinity through halogen bonding or electronic effects. The compound's primary function is chemical—serving as a boron source for cross-coupling reactions to synthesize biologically active molecules.
|
|---|---|
| ln Vitro |
In vitro, 2-fluorophenylboronic acid exhibits no intrinsic pharmacological activity as it is a chemical reagent. However, boronic acids have been investigated as inhibitors of fatty acid amide hydrolase (FAAH). The compound is used as a reactant in the synthesis of biologically active biphenyls and other pharmaceutical intermediates. In Suzuki-Miyaura coupling reactions, it achieves site-selective arylation. The compound itself is not tested in cell-based assays for pharmacological effects. Its value lies in its ability to introduce a fluorophenyl group into drug-like molecules through cross-coupling reactions.
|
| ln Vivo |
2-Fluorophenylboronic acid does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used exclusively as a chemical reagent in organic synthesis. Any in vivo effects would be associated with the final products synthesized from this intermediate, not with the intermediate itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a versatile fluorinated arylboronic acid for the construction of complex molecules with potential therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme assays for 2-fluorophenylboronic acid are not standard as the compound is primarily a synthetic reagent. However, boronic acids can be evaluated as FAAH inhibitors using a standard protocol: FAAH enzyme is incubated with the substrate [¹⁴C]-anandamide or a fluorogenic substrate in the presence of varying concentrations of the boronic acid. Reactions are terminated, and product formation is quantified by scintillation counting or fluorescence measurement. IC₅₀ values are calculated from dose-response curves. For Suzuki-Miyaura coupling, typical conditions involve reacting the compound with aryl halides in the presence of a palladium catalyst and a base.
|
| Cell Assay |
In vitro cell culture experiments with 2-fluorophenylboronic acid are not standard as the compound is a synthetic reagent. When the compound is used to synthesize drug candidates (e.g., FAAH inhibitors), those products may be tested in cell culture using standard protocols. Typically, final compounds are dissolved in DMSO and diluted in culture medium. Cells are incubated for 24-72 hours, and effects on cell viability, enzyme activity, or specific signaling pathways are measured. The intermediate itself is not evaluated in cellular systems. Cytotoxicity may be assessed using MTT or LDH release assays.
|
| Animal Protocol |
In vivo animal studies are not conducted with 2-fluorophenylboronic acid, as it is a research reagent for chemical synthesis. When the compound is used to synthesize drug candidates, those final products undergo standard preclinical evaluation. Typical protocols for drug candidates include pharmacokinetic studies in rodents (oral or intravenous administration, blood sampling for LC-MS/MS analysis), efficacy studies in disease models (e.g., pain models for FAAH inhibitors), and toxicology studies. These studies evaluate the safety and efficacy of the final drug molecules, not the synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-fluorophenylboronic acid are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 139.92, logP -0.49, moderate water solubility), the compound would be expected to have moderate oral bioavailability if administered. Boronic acids can form reversible covalent adducts with proteins and may have complex pharmacokinetics. The compound would likely undergo metabolism via oxidative deboronation and cytochrome P450-mediated oxidation. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-fluorophenylboronic acid indicate that it causes skin irritation (H315) and has a signal word of "Warning". Precautionary measures include avoiding inhalation, wearing protective gloves and eye protection, and washing thoroughly after handling. The compound should be handled in a fume hood with appropriate personal protective equipment. No acute toxicity data are available. The compound is not intended for drug, household, or other uses. It should be stored in a cool, dry place away from moisture and strong oxidizing agents.
|
| Additional Infomation |
2-Fluorophenylboronic acid is a widely used building block in medicinal chemistry for the synthesis of biologically active biphenyls and other pharmaceutical intermediates. It is employed in Suzuki-Miyaura cross-coupling reactions, rhodium-catalyzed enantioselective addition reactions, and the preparation of boronic acid-based enzyme inhibitors such as FAAH inhibitors. The fluorine substituent enhances the compound's utility by modulating electronic properties and enabling selective reactions. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a boron source for the synthesis of biologically active molecules.
|
| Molecular Formula |
C6H6BFO2
|
|---|---|
| Molecular Weight |
139.92
|
| Exact Mass |
140.044
|
| CAS # |
1993-03-9
|
| PubChem CID |
2734354
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
267.8±42.0 °C at 760 mmHg
|
| Melting Point |
101-110 °C(lit.)
|
| Flash Point |
115.8±27.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.509
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
110
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(C1=CC=CC=C1F)(O)O
|
| InChi Key |
QCSLIRFWJPOENV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6BFO2/c8-6-4-2-1-3-5(6)7(9)10/h1-4,9-10H
|
| Chemical Name |
(2-fluorophenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1469 mL | 35.7347 mL | 71.4694 mL | |
| 5 mM | 1.4294 mL | 7.1469 mL | 14.2939 mL | |
| 10 mM | 0.7147 mL | 3.5735 mL | 7.1469 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
